Kymera Therapeutics (KYMR) announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics assumed with an Overweight at Barclays
- Mizuho biotech analysts hold an analyst/industry conference call
- Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones
- Kymera Therapeutics outlines 2026 anticipated milestones
- Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors